Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 544

Related Citations for PubMed (Select 17646619)

1.

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, Lane R.

Neurology. 2007 Jul 24;69(4 Suppl 1):S14-22.

PMID:
17646619
2.

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R.

Int J Geriatr Psychiatry. 2007 May;22(5):456-67.

PMID:
17380489
3.

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.

Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT.

Clin Drug Investig. 2010;30(1):41-9. doi: 10.2165/11531270-000000000-00000.

PMID:
19995097
4.

Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.

Grossberg G, Sadowsky C, Fröstl H, Frölich L, Nagel J, Tekin S, Zechner S, Ros J, Orgogozo JM.

Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):158-64.

PMID:
19484917
5.

Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.

Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK.

Neurology. 2007 Jul 24;69(4 Suppl 1):S23-8.

PMID:
17646620
6.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review.

PMID:
19370562
7.

A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.

Cummings J, Winblad B.

Expert Rev Neurother. 2007 Nov;7(11):1457-63. Review.

PMID:
17997695
8.

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.

Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R.

Curr Med Res Opin. 2008 Sep;24(9):2561-74. doi: 10.1185/03007990802328142 . Epub 2008 Jul 31.

PMID:
18674411
9.

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.

Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, Fillit H, Blesa R.

Int J Geriatr Psychiatry. 2007 May;22(5):485-91.

PMID:
17407176
10.

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.

Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X.

Dement Geriatr Cogn Disord. 2010;29(5):406-12. doi: 10.1159/000296073. Epub 2010 May 21.

PMID:
20502014
11.

Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.

Winblad B, Machado JC.

Expert Opin Drug Deliv. 2008 Dec;5(12):1377-86. doi: 10.1517/17425240802542690 . Review.

PMID:
19040398
12.

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.

Grossberg GT, Olin JT, Somogyi M, Meng X.

Int J Clin Pract. 2011 Apr;65(4):465-71. doi: 10.1111/j.1742-1241.2011.02641.x. Epub 2011 Feb 11.

PMID:
21309961
13.

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.

Darreh-Shori T, Jelic V.

Expert Opin Drug Saf. 2010 Jan;9(1):167-76. doi: 10.1517/14740330903439717. Review.

PMID:
20021294
14.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

PMID:
22068922
15.

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

Farlow MR, Alva G, Meng X, Olin JT.

Curr Med Res Opin. 2010 Feb;26(2):263-9. doi: 10.1185/03007990903434914.

PMID:
19929593
16.

Rivastigmine exposure provided by a transdermal patch versus capsules.

Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S.

Curr Med Res Opin. 2007 Dec;23(12):3199-204.

PMID:
18001519
17.

[Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].

Schmidt R, Alf C, Bancher C, Benke T, Berek K, Dal-Bianco P, Führwürth G, Imarhiagbe D, Jagsch C, Lechner A, Rainer M, Reisecker F, Rotaru J, Uranüs M, Walter A, Winkler A, Wuschitz A.

Neuropsychiatr. 2009;23(1):58-63. German.

PMID:
19272293
18.

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.

Kurz A, Farlow M, Lefèvre G.

Int J Clin Pract. 2009 May;63(5):799-805. doi: 10.1111/j.1742-1241.2009.02052.x. Review.

19.

A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.

Articus K, Baier M, Tracik F, Kühn F, Preuss UW, Kurz A.

Int J Clin Pract. 2011 Jul;65(7):790-6. doi: 10.1111/j.1742-1241.2011.02713.x. Epub 2011 Jun 6.

PMID:
21645184
20.

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.

Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT.

Curr Med Res Opin. 2010 Oct;26(10):2441-7. doi: 10.1185/03007995.2010.513849.

PMID:
20828359
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk